Bridging the gap between academic research and commercial success requires more than breakthrough science — it demands intentional alignment between discovery and real-world application. Too often, transformative innovations stall not because they lack merit, but because commercial strategy, ecosystem support, and early market validation enter the conversation too late. By fostering earlier collaboration between researchers, investors, and industry leaders — and by building strong network infrastructure that supports translation — institutions can dramatically increase the likelihood that scientific discoveries evolve into scalable, impactful solutions. When commercialization is viewed not as a departure from academia but as an extension of it, research achieves its highest potential: meaningful, measurable impact beyond the lab.

I’m excited to share a deeper look into my journey across biomedical engineering, GMP manufacturing, policy, and entrepreneurial real estate. From research and publications in neuroengineering to process leadership at Lonza and Zoetis, and hands-on stewardship through Highlanders Capital Three, my focus has been consistent: build what matters and govern with integrity. If our paths overlap in health, manufacturing, governance, or operations, I’d welcome a conversation. Here is my biography.

I'm proud to share a glimpse into my journey spanning over 40 years across engineering, manufacturing, 3D printing, and entrepreneurial ventures. From founding Pure Air Systems to empowering students through 3D printing camps, every step has been rooted in innovation, integrity, and a desire to create meaningful impact. Here is my biography.

Thrilled to share my professional biography, which captures the arc of my 30+ year journey across life sciences, innovation, strategy, and global health. I’ve had the honor of collaborating with visionary leaders and organizations to unlock transformative value at the intersection of science, business, and impact.

Peter Payne is a highly accomplished executive with over 30 years of leadership experience in the pharmaceutical, biotechnology, and contract research organization (CRO) industries. Known for his integrity and results-driven approach, Peter has successfully led organizations through periods of significant growth and transformation. With deep expertise in drug development, clinical trials, and corporate strategy, he has built a strong reputation for driving innovation and strategic partnerships. His leadership spans notable roles, including Vice President at Optum, President of Gennaker Bio, and CEO at multiple biotech companies. Peter’s ability to communicate complex strategies and foster cross-functional collaboration has made him a respected figure in the life sciences industry.